Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Protein of vascular endothelial growth inhibitor 174 inhibits epithelial-mesenchymal transition in renal cell carcinoma in vivo

Zhao, Qiang, Deng, Xiaohu, Hong, Baoan, Wang, Feng, Tang, Xinxin, Yang, Yong, Gong, Kan, Ye, Lin, Jiang, Wen G. and Zhang, Ning 2017. Protein of vascular endothelial growth inhibitor 174 inhibits epithelial-mesenchymal transition in renal cell carcinoma in vivo. Anticancer Research 37 (8) , pp. 4269-4275. 10.21873/anticanres.11819

[img]
Preview
PDF - Published Version
Download (2MB) | Preview

Abstract

Background: Vascular endothelial growth inhibitor (VEGI) is a member of the tumor necrosis factor superfamily, identified as an anti-angiogenic cytokine. However, the effect of VEGI on epithelial–mesenchymal transition (EMT) in renal cell carcinoma (RCC) is still unknown. Materials and Methods: In this study, protein VEGI174 was designed and synthesized. Renal cell carcinoma A498 cells were implanted into immune-deficient mice to establish tumor models. Two groups were included: control group treated with saline, and VEGI174-treated group. Data of tumor growth were collected every 3 to 4 days. Two weeks later, the tumor specimens were harvested for immunohistochemical staining of EMT markers (E-cadherin, N-cadherin, vimentin). Results: Compared to the saline-treated group, the VEGI174-treated group showed significant inhibition of tumor growth (p<0.05). The expression of E-cadherin was significantly higher in the VEGI174-treated group compared to the saline-treated group (p<0.01). However, the expression of N-cadherin and vimentin were reduced in the VEGI174-treated group. Conclusion: Our findings indicate that VEGI174 prevents progression and tumor metastasis through inhibiting EMT in RCC in vivo. This may provide a new approach for the treatment of RCC.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
Publisher: International Institute of Anticancer Research (IIAR)
ISSN: 0250-7005
Funders: the National Natural Science Foundation of China, grant No. 81372138 and Cancer Research Wales
Date of First Compliant Deposit: 15 January 2018
Date of Acceptance: 24 April 2017
Last Modified: 19 Nov 2019 17:44
URI: http://orca.cf.ac.uk/id/eprint/103034

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics